{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T17:57:16Z","timestamp":1783187836185,"version":"3.54.6"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-025-10578-z","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T02:11:24Z","timestamp":1766715084000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluating the role of mavacamten in symptomatic non-obstructive hypertrophic cardiomyopathy: the ODYSSEY-HCM trial"],"prefix":"10.1007","volume":"31","author":[{"given":"Kaveh","family":"Hosseini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Kazemian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivadasanpillai","family":"Harikrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron L.","family":"Sverdlov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baljash S.","family":"Cheema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra Hassan Abdulla","family":"Juma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tor","family":"Biering-S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avishay","family":"Grupper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"issue":"4","key":"10578_CR1","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jacc.2021.12.002","volume":"79","author":"BJ Maron","year":"2022","unstructured":"Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA, Rowin EJ, Maron MS, Sherrid MV (2022) Diagnosis and evaluation of hypertrophic cardiomyopathy: JACC State-of-the-Art review. J Am Coll Cardiol 79(4):372\u2013389. https:\/\/doi.org\/10.1016\/j.jacc.2021.12.002","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10578_CR2","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1002\/ejhf.3291","volume":"26","author":"L Velicki","year":"2024","unstructured":"Velicki L, Popovic D, Okwose NC, Preveden A, Tesic M, Tafelmeier M, Charman SJ, Barlocco F, MacGowan GA, Seferovic PM, Filipovic N, Ristic A, Olivotto I, Maier LS, Jakovljevic DG (2024) Sacubitril\/valsartan for the treatment of non-obstructive hypertrophic cardiomyopathy: an open label randomized controlled trial (SILICOFCM). Eur J Heart Fail 26(6):1361\u20131368. https:\/\/doi.org\/10.1002\/ejhf.3291","journal-title":"Eur J Heart Fail"},{"issue":"23","key":"10578_CR3","doi-asserted-by":"publisher","first-page":"e1239","DOI":"10.1161\/cir.0000000000001250","volume":"149","author":"SR Ommen","year":"2024","unstructured":"Ommen SR, Ho CY, Asif IM, Balaji S, Burke MA, Day SM, Dearani JA, Epps KC, Evanovich L, Ferrari VA, Joglar JA, Khan SS, Kim JJ, Kittleson MM, Krittanawong C, Martinez MW, Mital S, Naidu SS, Saberi S, Semsarian C, Times S, Waldman CB (2024) The management of hypertrophic cardiomyopathy: A report of the American heart Association\/American college of cardiology joint committee on clinical practice guidelines. Circulation 149(23):e1239\u2013e1311. https:\/\/doi.org\/10.1161\/cir.0000000000001250. 2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR Guideline for","journal-title":"Circulation"},{"issue":"37","key":"10578_CR4","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","volume":"44","author":"E Arbelo","year":"2023","unstructured":"Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, Bezzina CR, Biagini E, Blom NA, de Boer RA, De Winter T, Elliott PM, Flather M, Garcia-Pavia P, Haugaa KH, Ingles J, Jurcut RO, Klaassen S, Limongelli G, Loeys B, Mogensen J, Olivotto I, Pantazis A, Sharma S, Van Tintelen JP, Ware JS, Kaski JP (2023) 2023 ESC guidelines for the management of cardiomyopathies. Eur Heart J 44(37):3503\u20133626. https:\/\/doi.org\/10.1093\/eurheartj\/ehad194","journal-title":"Eur Heart J"},{"issue":"10253","key":"10578_CR5","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/s0140-6736(20)31792-x","volume":"396","author":"I Olivotto","year":"2020","unstructured":"Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P, Saberi S, Lakdawala NK, Wheeler MT, Owens A, Kubanek M, Wojakowski W, Jensen MK, Gimeno-Blanes J, Afshar K, Myers J, Hegde SM, Solomon SD, Sehnert AJ, Zhang D, Li W, Bhattacharya M, Edelberg JM, Waldman CB, Lester SJ, Wang A, Ho CY, Jacoby D (2020) Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 396(10253):759\u2013769. https:\/\/doi.org\/10.1016\/s0140-6736(20)31792-x","journal-title":"Lancet"},{"issue":"20","key":"10578_CR6","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","volume":"390","author":"MS Maron","year":"2024","unstructured":"Maron MS, Masri A, Nassif ME, Barriales-Villa R, Arad M, Cardim N, Choudhury L, Claggett B, Coats CJ, D\u00fcngen HD, Garcia-Pavia P, Hag\u00e8ge AA, Januzzi JL, Lee MMY, Lewis GD, Ma CS, Michels M, Olivotto I, Oreziak A, Owens AT, Spertus JA, Solomon SD, Tfelt-Hansen J, van Sinttruije M, Veselka J, Watkins H, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Abraham TP (2024) Aficamten for symptomatic obstructive hypertrophic cardiomyopathy. N Engl J Med 390(20):1849\u20131861. https:\/\/doi.org\/10.1056\/NEJMoa2401424","journal-title":"N Engl J Med"},{"key":"10578_CR7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2505927","author":"MY Desai","year":"2025","unstructured":"Desai MY, Owens AT, Abraham T, Olivotto I, Garcia-Pavia P, Lopes RD, Elliott P, Fernandes F, Verheyen N, Maier L, Meder B, Azevedo O, Kitaoka H, Wolski K, Wang Q, Jaber W, Mitchell L, Myers J, Rano T, Gong Z, Zhong Y, Carter-Bonanza S, Florea V, Aronson R, Nissen SE (2025) Mavacamten in symptomatic nonobstructive hypertrophic cardiomyopathy. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2505927","journal-title":"N Engl J Med"},{"key":"10578_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.08.017","author":"MY Desai","year":"2025","unstructured":"Desai MY, Olivotto I, Abraham T, Nissen SE, Garcia-Pavia P, Lopes RD, Elliott PM, Fernandes F, de Barros Correia E, Barriales-Villa R, Zorio E, Arad M, Shin SH, Verheyen N, Meder B, Azevedo O, Kitaoka H, Wolski K, Wang Q, Suryawanshi B, Wang Z, Florea V, Aronson R, Owens AT (2025) Effects of Mavacamten on cardiac biomarkers in nonobstructive hypertrophic cardiomyopathy: insights from the ODYSSEY-HCM trial. J Am Coll Cardiol. https:\/\/doi.org\/10.1016\/j.jacc.2025.08.017","journal-title":"J Am Coll Cardiol"},{"key":"10578_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.08.019","author":"MY Desai","year":"2025","unstructured":"Desai MY, Okushi Y, Jadam S, Olivotto I, Owens A, Nissen SE, Popovic ZB, Garcia-Pavia P, Lopes RD, Elliott PM, Fernandes F, Geske JB, Maier L, Wolski K, Wang Q, Jaber W, Gong Z, Florea V, Fronheiser M, Leva A, Aronson R, Abraham T (2025) Echocardiographic changes with Mavacamten in nonobstructive hypertrophic cardiomyopathy: exploratory insights from the ODYSSEY-HCM trial. J Am Coll Cardiol. https:\/\/doi.org\/10.1016\/j.jacc.2025.08.019","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"10578_CR10","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","volume":"75","author":"CY Ho","year":"2020","unstructured":"Ho CY, Mealiffe ME, Bach RG, Bhattacharya M, Choudhury L, Edelberg JM, Hegde SM, Jacoby D, Lakdawala NK, Lester SJ, Ma Y, Marian AJ, Nagueh SF, Owens A, Rader F, Saberi S, Sehnert AJ, Sherrid MV, Solomon SD, Wang A, Wever-Pinzon O, Wong TC, Heitner SB (2020) Evaluation of Mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 75(21):2649\u20132660. https:\/\/doi.org\/10.1016\/j.jacc.2020.03.064","journal-title":"J Am Coll Cardiol"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-025-10578-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-025-10578-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-025-10578-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T02:11:27Z","timestamp":1766715087000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-025-10578-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10578"],"URL":"https:\/\/doi.org\/10.1007\/s10741-025-10578-z","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,26]]},"assertion":[{"value":"22 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Aaron L Sverdlov is supported by the Heart Foundation of Australia Future Leader Fellowship (Award ID 106025). All other authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"AI-based tools (ChatGPT-5 and Grammarly GO) were used exclusively for language editing and refinement. All text was reviewed and verified by the authors to ensure accuracy and integrity.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure of AI programs"}}],"article-number":"16"}}